Organic Process Research & Development
Communication
intensity) 212 (M+, 23), 194 (11), 105 (100), 91 (50), 77
(27), 65 (13), 51 (20).
intensity) 158 (M+, 1), 125 (7), 103 (10), 83 (25), 57 (100),
41 (33).
Cyclohexylmethyl Cyclohexanecarboxylate (3n). 1H NMR
(400 MHz, CDCl3) δ 0.90−1.03 (m, 2H), 1.11−1.34 (m, 6H),
1.40−1.49 (m, 2H), 1.58−1.78 (m, 9H), 1.84−1.92 (m, 2H),
2.26−2.32 (m, 1H), 3.87 (d, J = 6.4 Hz, 2H); 13C NMR (100
MHz, CDCl3) δ 25.5, 25.7, 26.4, 29.1, 29.7, 37.2, 43.3, 69.3,
176.2; MS (EI) m/z (relative intensity) 224 (M+, 1), 129 (13),
111 (15), 96 (100), 81 (76), 67 (25), 55 (90).
General Procedure 3: Pd/Xantphos-Catalyzed Oxida-
tion Reaction for the Synthesis of Nitrogen-Containing
Heterocycles under Argon (Table 4, entry 1). To a
solution of Pd(OAc)2 (11.2 mg, 0.05 mmol) and Xantphos
(28.9 mg, 0.05 mmol) in dry CH3CN (3 mL) was added
amino alcohol 5a (137.2 mg, 1.0 mmol) via syringe under
argon. The mixture was stirred at 80 °C for 48 h, and the
reaction was monitored by gas chromatography. The reaction
mixture was dried (MgSO4) and concentrated in vacuo, and
the residual oil was subjected to column chromatography over
silica gel (hexane/EtOAc = 4/1 v/v) to give 6a (99.6 mg, 85%
yield, Rf = 0.3).
3,5,5-Trimethylhexyl 3,5,5-Trimethylhexanoate (3p). Dia-
stereomeric mixture, 3p/3p′ = 60/40 as estimated by 1H NMR
analysis. 1H NMR (400 MHz, CDCl3, major isomer) δ 0.89 (s,
9H), 0.91 (s, 9H), 0.95 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.4
Hz, 3H), 1.01−1.12 (m, 2H), 1.21 (t, J = 4.0 Hz, 2H), 1.42−
1.48 (m, 1H), 1.56−1.68 (m, 2H), 2.01−2.15 (m, 2H), 2.27−
2.29 (m, 1H), 4.03−4.11 (m, 2H); 13C NMR (100 MHz,
CDCl3, major isomer) δ 22.4, 22.7, 26.2, 26.6, 27.0, 29.9, 31.0,
31.1, 37.9, 44.1, 50.5, 62.7, 173.3; 1H NMR (400 MHz,
CDCl3, minor isomer) δ 0.89 (s, 9H), 0.91 (s, 9H), 0.95 (d, J
= 6.4 Hz, 3H), 0.98 (d, J = 6.4 Hz, 3H), 1.01−1.12 (m, 2H),
1.25 (t, J = 4.0 Hz, 2H), 1.42−1.48 (m, 1H), 1.56−1.68 (m,
2H), 2.01−2.15 (m, 2H), 2.30−2.32 (m, 1H), 4.03−4.11 (m,
2H); 13C NMR (100 MHz, CDCl3, minor isomer) δ 22.5,
22.7, 26.2, 26.6, 27.0, 29.9, 31.0, 31.1, 37.9, 44.1, 51.0, 62.7,
173.3; MS (EI) m/z (relative intensity) 284 (M+, 1), 269 (5),
159 (23), 141 (25), 126 (32), 115 (42), 70 (83), 57 (100).
Indole (6a). 1H NMR (400 MHz, CDCl3) δ 6.55 (d, J = 1.2
Hz, 1H), 7.12−7.22 (m, 3H), 7.36 (d, J = 8.2 Hz, 1H), 7.66
(d, J = 8.2 Hz, 1H), 8.01 (br s, 1H); 13C NMR (100 MHz,
CDCl3) δ 111.0, 119.8, 120.7, 121.9, 124.1, 127.8, 135.7; MS
(EI) m/z (relative intensity) 117 (M+, 100), 90 (50), 89 (41),
58 (28).
1
5-Methylindole (6b). H NMR (400 MHz, CDCl3) δ 2.45
(s, 3H), 6.47 (d, J = 1.6 Hz, 1H), 7.02 (d, J = 8.0 Hz, 1H),
7.13 (d, J = 2.6 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.44 (s, 1H),
7.96 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ 21.4, 102.0,
110.6, 120.3, 123.6, 124.2, 128.1, 129.0, 134.0; MS (EI) m/z
(relative intensity) 131 (M+, 78), 130 (100), 103 (11), 77
(22), 65 (47), 51 (18).
1
γ-Butyrolactone (3s). H NMR (400 MHz, CDCl3) δ 2.28
(dquin, 2H), 2.50 (td, 2H), 4.36 (td, J = 7.6, 8.8 Hz, 2H); 13
C
5-Chloroindole (6c). H NMR (400 MHz, CDCl3) δ 6.49
1
NMR (100 MHz, CDCl3) δ 21.9, 27.5, 68.3, 177.6; MS (EI)
(d, J = 3.6 Hz, 1H), 7.15 (dd, J = 8.8, 1.6 Hz, 1H), 7.21 (d, J =
3.6 Hz, 1H), 7.29 (dd, J = 8.8, 1.6 Hz, 1H), 7.61 (s, 1H), 8.14
(br s, 1H); 13C NMR (100 MHz, CDCl3) δ 102.4, 111.9,
120.1, 122.3, 125.5, 128.9, 134.1; MS (EI) m/z (relative
intensity) 151 (M+, 100), 124 (11), 116 (23), 89 (30), 76
(17), 58 (15).
m/z (relative intensity) 86 (M+, 50), 56 (42), 42 (100).
1
Phthalide (3t). H NMR (400 MHz, CDCl3) δ 5.33 (s,
2H), 7.51 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.70 (t,
J = 7.6 Hz, 1H), 7.92 (d, J = 7.6 Hz, 1H); 13C NMR (100
MHz, CDCl3) δ 69.6, 122.1, 125.7, 129.0, 146.5, 171.1; MS
(EI) m/z (relative intensity) 134 (M+, 43), 105 (100), 77
(69), 51 (30).
General Procedure 4: Pd/Xantphos-Catalyzed Oxida-
tive Synthesis of Quinazolines from Diamine 7 and
Alcohols (Table 5). To a solution of Pd(OAc)2 (11.2 mg,
0.05 mmol) and Xantphos (28.9 mg, 0.05 mmol) in dry anisole
(3 mL) were successively added 1a (270.3 mg, 2.5 mmol) and
diamine 7 (122.2 mg, 1.0 mmol) via syringe under argon. The
mixture was stirred at 100 °C for 48 h, and the reaction was
monitored by gas chromatography. The reaction mixture was
dried (MgSO4) and concentrated in vacuo, and the residual oil
was subjected to column chromatography over silica gel
(hexane/EtOAc = 50/1 v/v) to give 8a (175.4 mg, 85%, Rf =
0.4).
Benzoic Acid (4a). 1H NMR (400 MHz, CDCl3) δ 7.48 (td,
J = 8.0, 2.0 Hz, 2H), 7.63 (tt, J = 8.0, 2.0 Hz, 1H), 8.13 (dt, J =
8.0, 2.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 128.5, 129.3,
130.2, 133.8, 172.4; MS (EI) m/z (relative intensity) 122 (M+,
83), 105 (100), 77 (82), 51 (60).
1
m-Chlorobenzoic Acid (4e). H NMR (400 MHz, CDCl3)
δ 7.43 (td, J = 7.6, 1.6 Hz, 1H), 7.60 (dt, J = 7.6, 1.6 Hz, 1H),
8.01 (dt, J = 7.6, 1.6 Hz, 1H), 8.10 (t, J = 1.6 Hz, 1H); 13C
NMR (100 MHz, CDCl3) δ 128.3, 129.8, 130.3, 130.9, 133.9,
134.7, 170.9; MS (EI) m/z (relative intensity) 156 (M+, 82),
139 (100), 111 (52), 75 (35), 50 (29).
1
2-Phenylquinazoline (8a). H NMR (400 MHz, CDCl3) δ
1
trans-Cinnamic Acid (4l). H NMR (400 MHz, CDCl3) δ
7.51−7.59 (m, 4H), 7.89−7.91 (m, 2H), 8.07 (dd, J = 8.2, 0.8
Hz, 1H), 8.62 (dd, J = 8.2, 2.0 Hz, 2H), 9.45 (s, 1H); 13C
NMR (100 MHz, CDCl3) δ 123.6, 127.1, 127.2, 128.5, 128.6,
130.6, 134.0, 138.0, 150.7, 160.4, 161.0; MS (EI) m/z (relative
intensity) 206 (M+, 100), 179 (56), 103 (30), 76 (34), 50
(25).
6.47 (d, J = 16.0 Hz, 1H), 7.25−7.43 (m, 3H), 7.56 (dd, J =
7.2, 2.0 Hz, 2H), 7.81 (d, J = 16.0 Hz, 1H); 13C NMR (100
MHz, CDCl3) δ 117.3, 128.4, 128.9, 130.7, 134.0, 147.1,
172.5; MS (EI) m/z (relative intensity) 148 (M+, 75), 147
(100), 131 (25) 103 (47), 77 (50), 51 (62).
1
Cyclohexanecarboxylic Acid (4n). H NMR (400 MHz,
2-(4-Methoxyphenyl)quinazoline (8b). 1H NMR (400
MHz, CDCl3) δ 3.87 (s, 3H), 7.03 (dd, J = 6.8, 2.0 Hz,
2H), 7.52 (td, J = 6.8, 1.6 Hz, 1H), 7.83 (td, J = 6.8, 2.0 Hz,
2H), 8.02 (dd, J = 6.8, 2.0 Hz, 1H), 8.87 (dd, J = 6.8, 2.0 Hz,
2H), 9.38 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 55.3,
113.9, 123.2, 126.7, 127.0, 128.3, 130.1, 130.7, 133.9, 150.7,
160.3, 160.8, 161.8; MS (EI) m/z (relative intensity) 236 (M+,
100), 221 (17), 193 (13), 166 (12), 118 (14), 96 (15).
CDCl3) δ 1.22−1.34 (m, 3H), 1.41−1.48 (m, 2H), 1.63−1.66
(m, 1H), 1.75−1.77 (m, 2H), 1.92−1.96 (m, 2H), 2.30−2.36
(m, 1H); 13C NMR (100 MHz, CDCl3) δ 25.3, 25.7, 28.8,
42.9, 182.5; MS (EI) m/z (relative intensity) 128 (M+, 22), 83
(50), 73 (62), 55 (100), 41 (70).
1
3,5,5-Trimethylhexanoic Acid (4p). H NMR (400 MHz,
CDCl3) δ 0.87 (s, 9H), 1.02 (d, J = 6.4 Hz, 3H), 1.12−1.34
(m, 2H), 2.06−2.40 (m, 3H); 13C NMR (100 MHz, CDCl3) δ
22.6, 26.8, 29.9, 31.0, 43.7, 50.5, 179.4; MS (EI) m/z (relative
1
2-(4-Nitrophenyl)quinazoline (8c). H NMR (400 MHz,
CDCl3) δ 7.73 (t, J = 7.6 Hz, 1H), 8.00 (t, J = 7.6 Hz, 2H),
F
Org. Process Res. Dev. XXXX, XXX, XXX−XXX